Merck & Co (NY:MRK)

The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500...

Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Topics Artificial Intelligence Economy Stocks

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

Build a resilient dividend portfolio with Merck (MRK). It offers a strong 3.86% yield, consistent growth, and is backed by top-tier profitability and financial health.

Topics Intellectual Property

Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Case for Dividend Investors ↗

November 06, 2025

Via Chartmill

3 Reasons Investors Love Merck (MRK)

November 05, 2025

Although Merck (currently trading at $84.57 per share) has gained 7% over the last six months, it has trailed the S&P 500’s 21.3% return during that period. This may have investors wondering how to...

Via StockStory

Topics Stocks Supply Chain

Merck Stock Rises Upon Receipt Of $700M In Funding For Experimental Cancer Drug ↗

November 04, 2025

Via Stocktwits

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

MarketMinute: The Rise of Precision Swine Farming – A New Frontier in Agri-Tech Investment

November 05, 2025

The global agricultural landscape is undergoing a profound transformation, with specialized niche markets emerging as significant drivers of innovation and investment. Among these, the precision swine...

The burgeoning market for obesity and diabetes treatments, particularly GLP-1 receptor agonists, is witnessing a dramatic divergence in fortunes among its leading players. As of November 5, 2025, Novo...

Topics Artificial Intelligence Supply Chain

Obesity Drugmakers Face Shifting Tides: Novo Nordisk Plunges While Eli Lilly Soars

November 05, 2025

Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...

Topics Economy

AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns

November 05, 2025

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

Topics Artificial Intelligence Intellectual Property

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

Investors were unimpressed with Merck's Q3 financial results.

Topics Artificial Intelligence

Why Merck Is Sinking This Week ↗

November 04, 2025

Via The Motley Fool

Topics Intellectual Property

Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

November 04, 2025

From Merck & Co., Inc.

Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody

November 04, 2025

From Merck & Co., Inc.

With yields of up to 7%, this trio of high-yield stocks are all industry-leading companies.

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

November 04, 2025

Via The Motley Fool

Topics Energy Stocks

Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.

November 03, 2025

From Merck Sharp & Dohme

The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...

AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio

November 01, 2025

Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant...

Topics Animal Testing Artificial Intelligence Economy

Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout

October 31, 2025

San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of...

Topics Intellectual Property

AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs

October 31, 2025

The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late...

Topics Artificial Intelligence Supply Chain

AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future

October 31, 2025

Merck Q3 2025 Earnings Call Transcript

Topics Animal Testing Artificial Intelligence Economy

Merck Q3 2025 Earnings Call Transcript ↗

October 31, 2025

Via The Motley Fool

Topics Earnings

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗

October 30, 2025

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.

Via Benzinga

Topics ETFs

Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗

October 30, 2025

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome...

Via Benzinga

Topics Economy

Merck Ready For Larger Than $15 Billion Deals, Raises Annual Profit Outlook ↗

October 30, 2025

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid mixed product performance.

Via Benzinga

Merck’s (NYSE:MRK) Q3 Sales Top Estimates

October 30, 2025

Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 3.7% year on year to $17.28 billion. The company expects the full year’s revenue to be...

Via StockStory

Merck & Co. Inc. (NYSE:MRK) Q3 2025 Earnings Beat Expectations Despite Stock Decline ↗

October 30, 2025

Merck Q3 2025 earnings beat estimates with strong sales and EPS growth, driven by KEYTRUDA and WINREVAIR, yet shares fell on guidance.

Via Chartmill

Topics Earnings

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 30, 2025

Via Benzinga

Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain ↗

October 30, 2025

The company sells a notable vaccine to prevent human papillomavirus. But sales are struggling.

Via Investor's Business Daily

Topics Earnings Stocks

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

October 30, 2025

From Merck & Co., Inc.